Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial
NCT ID: NCT06156176
Last Updated: 2025-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2025-04-01
2026-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pulmonary Rehabilitation for Long COVID (Post COVID-19 Condition)
NCT05244044
Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients with Long COVID
NCT06822179
Pulmonary Rehabilitation Post-COVID-19
NCT05003271
Effect of Pulmonary Rehabilitation and Physical Activity on Long COVID (PuReCOVID)
NCT07046442
Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Post-COVID-19 Syndrome: A Randomized Controlled Trial
NCT06156202
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All participants will be informed that they are part of an observational study designed to follow the natural progression of Long COVID and to evaluate the costs associated with standard post-COVID-19 treatments. This includes both the COVIDEx and SoC groups. The objective is to ensure comprehensive data collection on health outcomes and healthcare utilization across the spectrum of post-COVID care. By blinding patients to the presence of the experimental group, the modified Zelen design will mitigate the effects of feeling disappointed, frustrated, or discouraged about being assigned SoC, which is important given the primary outcome is a subjective, patient reported outcome measure (detection bias). This approach will also reduce the likelihood that patients in the SoC group begin self-motivated programs trying to mimic the intervention (performance bias) since there is no standard of care for this population. Upon completion of the study, both groups will attend a disclosure interview where the randomized nature of the study will be revealed, the rationale for this deception/treatment delay will be provided and full informed consent to use their data for the RCT will be sought. The deception disclosure interview for participants will occur over the phone. A member of the Parkwood research team (research coordinator or research assistant) will telephone each control group participant upon completion of the participant's study procedures and disclose the deception to participants. While on the phone, a copy of the debriefing letter of information/consent (LOI/C) will be emailed to the participant, for the participant to read. The research coordinator or assistant will answer any questions that the participant has and give the participant as much time is needed to sign the consent form. SoC patients will then be offered the COVIDEx intervention. The treatment period will be 8 weeks, with 2 COVIDEx sessions per week.
Outcomes will be collected at baseline, 4-, 8-, 12- and 24- weeks follow-up during assessment sessions. Outcomes include feasibility measures and clinical outcomes, including a transcranial magnetic stimulation (TMS) brain function test. Qualitative one-on-one interviews will explore the acceptability of the intervention and barriers/facilitators to intervention adherence and study retention. Only participants randomized to the COVIDEx group will be asked to participate in the interviews. The study team will not gather data from control group participants if they choose to participate in the COVIDEx intervention.
Measurement of post-exertional malaise (PEM): Some participants may indicate that they experience PEM on the demographic questionnaire. PEM is defined as the worsening of symptoms (such as difficulty thinking, problems sleeping, sore throat, headaches, feeling dizzy, or severe tiredness) after a physical or mental activity that would not have caused a problem before COVID-19 infection and subsequent post-COVID-19 fatigue. We will address this in the trial by: (1) Pacing the COVIDEx session to prevent over-exertion. A pacing strategy and protocol may reduce exacerbation of PEM for those with Long COVID. Pacing will entail frequently gathering subjective measurements of intensity from participants, as well as ensuring that all components of the session (i.e., cardio, strength training) have adequate rest and recovery in between periods of more intense activity. Participants will inform the physiotherapist or exercise instructor of their resting heart rate and blood oxygen levels before each session and after each component of the session, which will help determine exercise intensity and pacing. (2) Monitoring blood lactate levels in participants. All COVIDEx participants, throughout the COVIDEx sessions, will use an Apple Watch to monitor surrogate measures for their blood lactate levels (specifically, heart rate, blood oxygen, steps activity, and sleep). This device is required to be worn by participants as often as possible over the 24-week study period, but especially during each COVIDEx session. Monitoring surrogate measures for blood lactate enables examination of metabolic responses (i.e., mitochondrial dysfunction, reduced tissue oxygenation) in individuals with Long COVID, which could help prevent the onset of PEM by ensuring participants do not exceed a threshold that could induce PEM. Specifically, our objective of monitoring surrogate measures for blood lactate is for safety purposes to prevent overreaching in participants with Long COVID. Participants will be asked to inform the physiotherapist or exercise professional of their blood oxygen levels and heart rate at various time points throughout the COVIDEx intervention, so the instructor can gauge intensity and modify exercise intensity as needed. The instructor will have a lactate range table on hand to ensure participants are within the Safe and Functional Overreaching zones (stated within the research plan) and will approximate this based on participant's blood oxygen levels. The Apple Watches will be provided to participants at no cost to them. Participants have the choice to use their own Apple Watch or can be provided one from the study team. Participants may be required to input basic profile information on the wearable device, such as email, age, height, weight, and/or gender to personalize the tracking features.
To also assist in assessing PEM and fatigue, an ecological momentary assessment (EMA) design will be used to ask participants how they're feeling at random time-points after participating in the COVIDEx sessions (up to the 24-week follow-up). For comparison, participants in the control group will also be administered the EMA questions. These questions are based off the DePaul Symptom Questionnaire-SF. Participants will be asked to download the ExpiWell app, which will be the way of administering the questions at random time-points. Collecting EMA data will assist the researchers in identifying potential cases of PEM and/or any other adverse or serious adverse events. EMA data will be collected for 24 weeks once the participant signs the LOI and agrees to participate in the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
COVIDEx
This group will receive two 50-minute rehabilitation sessions per week for 8 weeks.
COVIDEx
The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
Standard of Care
This group will receive standard of care (no intervention) for the 8-week intervention period.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVIDEx
The COVIDEx intervention was developed by triangulating patient preferences/needs, clinicians' expertise, and best current evidence specific to Long COVID and adapted from interventions for other complex fatigue disorders, which are consistent with evidence informed practice. The program is delivered by trained instructors and comprises of two 50-minute sessions each week for eight weeks. The intervention is designed to be delivered virtually in groups of 6 patients, to eliminate travel requirements for the study. The components of the program are: (i) warm-up (1 min), (ii) cardio training (5 min), (iii) rest (3 min), (iv) balance training (5 min), (v) breathing exercises (3 min), (vi) cognitive training (5 min), (vii) strengthening training (5 min), and (viii) stretching (10min). The COVIDEx program will be paced in order to prevent post-exertional malaise (PEM) in participants.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide informed consent
* Can speak and understand English
* Documented history of SARS-CoV-2 infection (positive PCR/antigen test during acute illness or clinical diagnosis by physician during or after the acute illness)
* Fatigue symptoms within 3 months of COVID-19 infection, lasting at least 2 months
* Fatigue symptoms cannot be explained by an alternative diagnosis
* Fatigue symptoms may be new onset following initial recovery from an acute COVID-19 infection or persist from the initial illness
* Fatigue symptoms may have an episodic nature, fluctuate or relapse over time
* Minimal functional capability: able to walk 10-15 minutes and be recovered within 30-60 minutes or without significant post-exertional malaise (PEM)
* Has applicable technology to access Microsoft Teams and Webex (i.e., computer, laptop, tablet)
Exclusion Criteria
* Pre-existing physical, cognitive, and/or mental health conditions that make exercise contraindicated, consent unattainable, or that cause symptoms similar to those seen in post COVID-19 (e.g., major neurocognitive disorder, schizophrenia, chronic fatigue syndrome) that could affect data
* Inability to follow study procedures
* Pregnant and/or breastfeeding
* Received investigational agents as part of a separate study within 30 days of the screening visit
* Has any type of metal bodily implant in head or heart (i.e., pins, plates, pacemakers)
* Current participation in other studies related to COVID-19, exercise, and/or fatigue interventions OR participation within 30 days of the screening visit
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Western University, Canada
OTHER
Canadian Institutes of Health Research (CIHR)
OTHER_GOV
Lawson Research Institute of St. Joseph's
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pavlos Bobos, PhD
Role: PRINCIPAL_INVESTIGATOR
Western University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Parkwood Hospital - St. Joseph's Health Care London
London, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pouliopoulou DV, Macdermid JC, Saunders E, Peters S, Brunton L, Miller E, Quinn KL, Pereira TV, Bobos P. Rehabilitation Interventions for Physical Capacity and Quality of Life in Adults With Post-COVID-19 Condition: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2023 Sep 5;6(9):e2333838. doi: 10.1001/jamanetworkopen.2023.33838.
Pouliopoulou DV, Billias N, MacDermid JC, Miller E, O'Brien KK, Quinn KL, Malvankar-Mehta MS, Pereira TV, Cheung AM, Razak F, Stranges S, Bobos P. Prevalence of post-acute sequelae of SARS-CoV-2 infection in people living with HIV: a systematic review with meta-analysis. EClinicalMedicine. 2024 Dec 17;79:102993. doi: 10.1016/j.eclinm.2024.102993. eCollection 2025 Jan.
Pouliopoulou DV, Hawthorne M, MacDermid JC, Billias N, Miller E, Quinn K, Decary S, Razak FA, Cheung A, Galiatsatos P, Pereira TV, Bobos P. Prevalence and Impact of Postexertional Malaise on Recovery in Adults With Post-COVID-19 Condition: A Systematic Review With Meta-analysis. Arch Phys Med Rehabil. 2025 Aug;106(8):1267-1278. doi: 10.1016/j.apmr.2025.01.471. Epub 2025 Feb 5.
Saunders EG, Pouliopoulou DV, Miller E, Billias N, MacDermid JC, Brunton L, Pereira TV, Quinn KL, Bobos P. Rehabilitation interventions and outcomes for post-COVID condition: a scoping review. BMJ Public Health. 2025 Feb 26;3(1):e001827. doi: 10.1136/bmjph-2024-001827. eCollection 2025.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBPREFACER01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.